Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 13/20 | 0.86 |
| ▸ | FLT3 | P36888 | 14/20 | 0.80 |
| ▸ | KDR | P35968 | 7/20 | 0.65 |
| ▸ | FLT4 | P35916 | 4/20 | 0.65 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328239 | 1.00 | AURKB (0.86) | AURKBFLT3KDRFLT4KIT | |
| SCHEMBL15328033 | 0.93 | AURKB (1.00) | AURKBFLT3KDRFLT4KIT | |
| SCHEMBL15328034 | 0.93 | AURKB (1.00) | AURKBFLT3KDRFLT4KIT | |
| SCHEMBL15339405 | 0.90 | AURKB (0.71) | AURKBFLT3KDRFLT4KIT | |
| SCHEMBL16418190 | 0.90 | FLT3 (0.79) | AURKBFLT3KDRFLT4KIT | |
| SCHEMBL15327973 | 0.89 | FLT3 (1.00) | AURKBFLT3KDRFLT4KIT | |
| SCHEMBL15327975 | 0.89 | FLT3 (1.00) | AURKBFLT3KDRFLT4KIT | |
| SCHEMBL18060034 | 0.87 | AURKB (0.81) | AURKBFLT3KDRFLT4KIT | |
| SCHEMBL15327966 | 0.87 | FLT3 (1.00) | AURKBFLT3KDRFLT4KIT | |
| SCHEMBL15327965 | 0.87 | FLT3 (1.00) | AURKBFLT3KDRFLT4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | claimed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | claimed |
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ING2, CDK2, MAP3K20 | AURKB 100/4885FLT3 1086/4885KDR 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.